Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder (SAILLANCE2) (SAILLANCE2)

May 11, 2026 updated by: University Hospital, Lille

Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder

Post-traumatic stress disorder (PTSD) is characterized by hypervigilance. In particular, previous works suggest that patients tend to scan constantly the environment for possible threats. The present project aims at investigating such attentional bias in patients with PTSD using the change blindness paradigm that offers the interesting possibility of studying sensitivity to sudden changes using ecological stimuli. More precisely, the investigators will investigate whether patients are more sensitive than matched controls to sudden changes in the visual environment and whether this hypersensitivity is specific or even stronger when visual information has an emotional content. The attentional bias will be measured using motor responses (accuracy and speed to indicate the occurrence of a change by pressing a button) as well as eye movements.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lille, France, 59037
        • University Hospital, Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Thirty patients with PTSD and 30 participants exposed to trauma without PTSD will be asked to detect neutral or emotional changes in 96 scenes.

Description

Inclusion Criteria:

  • a diagnosis of PTSD based on the standard DSM-IV criteria,
  • normal or corrected vision.
  • clinically stable at the testing time

Exclusion Criteria:

  • history of neurological illness or trauma that occurred in the previous six months, - pregnant and nursing women,
  • drugs use in the last 24 hours,
  • an acute ocular disorder.
  • Participants will not be under tutorship, curatorship or deprived of liberty.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Controls
30 healthy controls without any psychiatric or neurological diagnosis
Post-Traumatic Stress Disorders (PTSD)
30 patients with PTSD (diagnosis based on the standard DSM criteria)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response time before the detection of neutral and emotional stimuli.
Time Frame: Baseline: one session
The explicit response of the participants will be measured with the response time before the detection of neutral and emotional stimuli.
Baseline: one session

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of correct detections compared with the missed detections and false alarms.
Time Frame: Baseline: one session
Performances will be measured by a sensitivity index (D prime) . This sensitivity index considers the number of correct detections compared with the missed detections and false alarms.
Baseline: one session
Total duration until the participant first fixed on a ROI.
Time Frame: Baseline: one session
The implicit response will be measured by the localization and duration of fixations. All fixations outside the recording field will be excluded. The main variable will be the mean latency of the first fixation in a region of interest (ROI). This variable corresponds to the total duration until the participant first fixed on a ROI.
Baseline: one session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Guillaume VAIVA, University Hospital, Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2014

Primary Completion (Actual)

May 5, 2020

Study Completion (Actual)

May 5, 2020

Study Registration Dates

First Submitted

April 26, 2018

First Submitted That Met QC Criteria

May 8, 2018

First Posted (Actual)

May 9, 2018

Study Record Updates

Last Update Posted (Actual)

May 14, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

August 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 2013_19.2
  • 2013-A01498-37 (Other Identifier: ID-RCB number, ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe